13F reference period
Q3 2026
Security Snapshot
Cogent Biosciences, Inc. - Common Stock (COGT) Institutional Ownership
CUSIP: 19240Q201
13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026
Institutions Reporting
144
Shares (Excl. Options)
60.31M
Full value: 60,314,713 · shares · 30 Sep 2026Price
$32.02
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- COGT on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 60,314,713
- Total 13F value
- $1,930,381,176
- Portfolio coverage rank
- 0%
- Share change
- +2,105,784
- Value change
- +$57,987,271
- Number of holders
- 144
- Shares outstanding
- 173,823,056
- SEC-reported price per share
- $30.08
- Insider filing price
- $30.08
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- COGT - Cogent Biosciences, Inc. - Common Stock is tracked under CUSIP 19240Q201.
- 144 institutions reported positions in Q3 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 320 to 144 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$7.5B
Full value: $7,497,711,066 · USD · 30 Jun 2026.$1.93B
Full value: $1,930,381,176 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 144 institutions filings for Q3 2026.
Security key
19240Q201
13F reference period
Q3 2026
13F holders
144
13D/G owners
11
CIK / CUSIP context first
Open Q3 2026 holders
COGT full holder history
Cogent Biosciences, Inc. SEC filings
Cogent Biosciences, Inc. company facts
Cogent Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 19240Q201:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
COGT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | $81,355,047 | 16,569,256 | FMR LLC | 31 Dec 2024 | |||
| Fairmount Funds Management LLC | 8.6% | -13% | $542,559,913 | -$31,973,650 | 15,356,918 | -5.6% | Fairmount Funds Management LLC | 31 Mar 2026 |
| BlackRock, Inc. | 8% | +21% | $526,051,538 | +$86,023,869 | 13,593,063 | +20% | BlackRock, Inc. | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $336,364,494 | 8,691,589 | Vanguard Capital Management | 30 Jun 2026 | |||
| TCG Crossover GP I, LLC | 4.8% | $97,621,606 | 6,798,162 | TCG Crossover GP I, LLC | 30 Sep 2025 | |||
| Kynam Capital Management, LP | 4.3% | -20% | $219,296,982 | -$61,214,156 | 6,165,223 | -22% | Kynam Capital Management, LP | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 4% | -52% | $82,625,042 | -$60,775,814 | 5,753,833 | -42% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Flynn James E | 2.9% | -48% | $193,736,225 | -$156,262,821 | 5,006,104 | -45% | Deerfield Mgmt, L.P. | 30 Jun 2026 |
| Venrock Healthcare Capital Partners II, L.P. | 4.2% | -27% | $44,463,093 | -$15,815,581 | 4,755,411 | -26% | Venrock Healthcare Capital Partners II, L.P. | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 2.3% | -76% | $45,325,875 | -$103,335,292 | 3,156,398 | -70% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| Commodore Capital LP | 1.8% | -77% | $99,699,331 | -$263,401,363 | 2,802,905 | -73% | Commodore Capital LP | 31 Dec 2025 |
As of 30 Sep 2026,
144
institutional investors reported holding
shares of
Cogent Biosciences, Inc. - Common Stock (COGT).
This represents
35%
of the company’s total
outstanding shares.
60.31M
Full value: 60,314,713 · shares · 30 Sep 2026173.82M
Full value: 173,823,056 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
31%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 8,131,026 | +0.73% | 0.01% | $260,355,453 |
| STATE STREET CORP | 4.5% | 7,770,149 | +12% | 0.01% | $248,800,171 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 7,448,057 | +0.48% | 0.01% | $238,486,785 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 4,477,194 | -0.71% | 0.01% | $143,387,232 |
| Invesco Ltd. | 1.9% | 3,223,848 | +24% | 0.01% | $103,227,613 |
| Pictet Asset Management Holding SA | 1.6% | 2,842,776 | +19% | 0.09% | $90,989,642 |
| Candriam S.C.A. | 1.1% | 1,959,168 | -6.2% | 0.28% | $62,961,762 |
| FRANKLIN TEMPLETON INC | 1.1% | 1,938,543 | +1091% | 0.01% | $61,044,720 |
| EMERALD ADVISERS, LLC | 0.93% | 1,613,541 | +0.64% | 1.4% | $51,665,583 |
| Siren, L.L.C. | 0.93% | 1,609,279 | -13% | 1.2% | $51,529,114 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.91% | 1,574,698 | +23% | 6.1% | $50,421,830 |
| AMERICAN CENTURY COMPANIES INC | 0.83% | 1,441,091 | +0.57% | 0.02% | $46,143,808 |
| VANGUARD FIDUCIARY TRUST CO | 0.71% | 1,229,646 | +1.3% | 0.01% | $39,373,265 |
| Assenagon Asset Management S.A. | 0.68% | 1,182,530 | -18% | 0.04% | $37,864,611 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 0.63% | 1,087,725 | +5.5% | 1.4% | $34,828,955 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.58% | 1,005,567 | -1.6% | 0.01% | $32,198,255 |
| RENAISSANCE TECHNOLOGIES LLC | 0.41% | 708,668 | -29% | 0.03% | $22,691,549 |
| BNP PARIBAS FINANCIAL MARKETS | 0.38% | 657,447 | 0.01% | $21,051,453 | |
| Aberdeen Group plc | 0.34% | 588,628 | +50% | 0.03% | $18,847,869 |
| RAYMOND JAMES FINANCIAL INC | 0.3% | 528,550 | -22% | 0% | $16,924,169 |
| Fiera Capital Corp | 0.3% | 516,751 | +0.96% | 0.07% | $16,546,367 |
| MORGAN STANLEY | 0.29% | 511,231 | -46% | 0% | $16,369,663 |
| NEUBERGER BERMAN GROUP LLC | 0.26% | 460,098 | +20% | 0.01% | $14,732,338 |
| TimesSquare Capital Management, LLC | 0.24% | 416,925 | -6.9% | 0.22% | $13,349,939 |
| Patient Square Capital LP | 0.21% | 361,927 | -15% | 1.8% | $11,588,903 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Headline period
Q3 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 60,314,713 | $1,930,381,176 | +$57,987,271 | $32.02 | 144 |
| 2026 Q2 | 193,735,023 | $7,497,711,066 | +$262,466,566 | $38.70 | 320 |
| 2026 Q1 | 186,329,242 | $7,169,929,269 | +$317,721,394 | $38.49 | 304 |
| 2025 Q4 | 174,084,958 | $6,184,105,170 | +$561,964,697 | $35.52 | 266 |
| 2025 Q3 | 159,224,831 | $2,286,403,568 | +$377,675,482 | $14.36 | 192 |
| 2025 Q2 | 135,519,487 | $973,045,860 | +$18,987,122 | $7.18 | 175 |
| 2025 Q1 | 133,492,788 | $799,614,961 | +$57,857,622 | $5.99 | 182 |
| 2024 Q4 | 121,716,056 | $949,488,255 | -$21,661,319 | $7.80 | 173 |
| 2024 Q3 | 121,834,182 | $1,316,352,629 | +$470,587 | $10.80 | 160 |
| 2024 Q2 | 121,381,737 | $1,023,259,146 | +$106,597,224 | $8.43 | 146 |
| 2024 Q1 | 109,208,822 | $733,878,161 | +$128,257,287 | $6.72 | 144 |
| 2023 Q4 | 90,814,821 | $533,992,647 | -$45,403,172 | $5.88 | 141 |
| 2023 Q3 | 90,861,393 | $885,844,189 | +$20,538,646 | $9.75 | 134 |
| 2023 Q2 | 88,529,694 | $1,048,151,896 | +$158,614,636 | $11.84 | 134 |
| 2023 Q1 | 75,176,767 | $810,346,243 | +$3,226,883 | $10.79 | 133 |
| 2022 Q4 | 74,675,712 | $863,268,307 | -$1,804,375 | $11.56 | 133 |
| 2022 Q3 | 73,734,143 | $1,100,096,408 | +$70,755,840 | $14.92 | 129 |
| 2022 Q2 | 70,081,829 | $632,136,824 | +$209,072,563 | $9.02 | 107 |
| 2022 Q1 | 47,217,562 | $353,580,440 | -$5,659,624 | $7.49 | 81 |
| 2021 Q4 | 44,899,168 | $385,164,997 | +$41,807,073 | $8.58 | 80 |
| 2021 Q3 | 36,797,124 | $309,606,147 | +$4,142,169 | $8.41 | 71 |
| 2021 Q2 | 34,971,040 | $283,623,000 | +$12,872,399 | $8.11 | 65 |
| 2021 Q1 | 34,431,767 | $303,253,000 | +$9,820,126 | $8.78 | 65 |
| 2020 Q4 | 33,524,756 | $376,481,000 | +$318,450,000 | $11.23 | 67 |